Therefore, for assessing to what extent the combinations that were tested in MCF-7 cells might reflect on general drug combination efficacy in ER+ BC, as well as for obtaining information regarding the potential pan-cancer sensitivity, we evaluated the screen-selected targets in three additional ER+ BC cell lines; ZR-75-1, BT-474, and T-47D; a TNBC cell line, MDA-MB-231; and two non-BC cell lines, LNCaP (prostate) and PANC1 (pancreas). The gene discussed is ESR1; the disease is breast cancer.